PRESS RELEASE 2009

• FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients

Results from a phase III pivotal study sub-analyses reported in European Urology show that…

• Ferring donates $3 million to the Royal Textile Academy of Bhutan

Frederik Paulsen, Chairman, Ferring Pharmaceuticals, announced a $3 million donation to the Royal Textile Academy of Bhutan…

• Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2010 Theme Announced

Ferring Pharmaceuticals is proud to announce the second Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) today…

• New Data Supports Significant Economic and Clinical Value of MENOPUR® in IVF

New data from an economic analysis presented today at this year’s European Society of Human Reproduction and Embryology (ESHRE) congress showed that…

• Ferring launches New International Fertility Media Award (FIMA) 2010

Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress…

• Ferring Pharmaceuticals announces new Board Member

Ferring Pharmaceuticals announced today that Dr. John Patterson CBE FRCP has been appointed as a new Board Member with immediate effect…

• Frost & Sullivan Accolade for Ferring Pharmaceuticals

The 2008 Frost & Sullivan European Human Growth Hormone Competitive Strategy Leadership Award is presented to Ferring Pharmaceuticals…

• FIRMAGON® (degarelix) is launched in Europe for the treatment of advanced prostate cancer

Today marks the European launch of FIRMAGON® (degarelix), a new treatment option in hormonal therapy for prostate cancer…

• Ferring Pharmaceuticals creates Executive Board

Today, Ferring Pharmaceuticals announced the creation of a new Executive Board…

• European Commission grants Ferring Pharmaceuticals approval of FIRMAGON® (degarelix) for treatment of prostate cancer

Ferring Pharmaceuticals announced today that it has received marketing authorisation from the European Commission, for FIRMAGON® (degarelix)…